🇺🇸 Rapid-Acting Insulin in United States

26 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Abortion Spontaneous — 4 reports (15.38%)
  2. Drug Exposure During Pregnancy — 3 reports (11.54%)
  3. Hyperglycaemia — 3 reports (11.54%)
  4. Hypoglycaemia — 3 reports (11.54%)
  5. Nausea — 3 reports (11.54%)
  6. Anaemia — 2 reports (7.69%)
  7. Asthenia — 2 reports (7.69%)
  8. Atrial Fibrillation — 2 reports (7.69%)
  9. Blood Glucose Increased — 2 reports (7.69%)
  10. Cardiac Failure — 2 reports (7.69%)

Source database →

Rapid-Acting Insulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Rapid-Acting Insulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rapid-Acting Insulin in United States?

Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.